Overview

Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Status:
Terminated
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the maximum tolerated dose of AVE9633 and to characterize the dose limiting toxicity(ies). Secondary objectives are to determine the anti-leukemia activity, the global safety and the PK profile.
Phase:
Phase 1
Details
Lead Sponsor:
Sanofi